Oyster Point Raises $93 Million for Phase 3 Trials of Novel Treatment for Dry Eye Disease

PRINCETON, N.J., February 26, 2019 – FLG Partner’s client, Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company has announced a $93 million Series B financing. The round was co-led by Invus Opportunities and Flying L Partners in collaboration with Falcon Vision. Existing investors New Enterprise Associates (NEA) and…Read More

Read More
PerfectServe Acquires Lightning Bolt

Feb. 5, 2019 ­— PerfectServe, a leading provider of cloud-based clinical communication and collaboration (CC&C) solutions, today announced the acquisition of FLG Partner client, Lightning Bolt Solutions, an AI-optimized physician shift scheduling technology for hospitals and health systems. The acquisition was announced, in tandem, with the acquisition of  CareWire, a mobile patient…Read More

Read More
Cortexyme Announces Key Leadership Appointments to Support Next Stage of Growth

FLG client, Cortexyme, a privately held, clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer’s disease (AD) and other degenerative disorders, announced effective January 2019, two key leadership appointments. Veteran clinical development professional Michael Detke, M.D., Ph.D., has been appointed Chief Medical Officer and Chris Lowe, a longtime…Read More

Read More
Soleno Therapeutics Announces $16.5 Million Private Placement

REDWOOD CITY, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) — FLG client, Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has entered into a definitive agreement with certain institutional and accredited investors to raise aggregate gross proceeds…Read More

Read More
Rothy’s Announces Revenues of $140 Million

FLG Partner’s consumer client, Rothy’s, where Stephanie Roberts is CFO, is expected to post revenues of $140 million according to a recent article from Bloomberg. In U.S. sales, Rothy’s has quickly eclipsed Tod’s ($88 million in North America last year), and now measures about a third of the size of the Crocs empire of…Read More

Read More